相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Validation of PDGFRβ and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma:: preclinical efficacy of the novel, orally available inhibitor dasatinib
Addolorata Maria Luce Coluccia et al.
BLOOD (2008)
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase
Francois Guilhot et al.
BLOOD (2007)
The prevalence and clinical implications of c-kit expression in plasma cell myeloma
G Pruneri et al.
HISTOPATHOLOGY (2006)
A phase II trial of imatinib in patients with refractory/relapsed myeloma
A Dispenzieri et al.
LEUKEMIA & LYMPHOMA (2006)
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
TA Carter et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis
K Mahtouk et al.
BLOOD (2004)
Critical role for hematopoietic cell kinase (Hck)-mediated phosphorylation of Gab1 and Gab2 docking proteins in interleukin 6-induced proliferation and survival of multiple myeloma cells
K Podar et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents
A Pandiella et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Requirements of src family kinase activity associated with CD45 for myeloma cell proliferation by interleukin-6
H Ishikawa et al.
BLOOD (2002)
分享论文
